Punit Dhillon

Punit Dhillon, Chairman and CEO of Skye Bioscience, shares insights on innovative obesity therapies targeting CB1 inhibition. He discusses the challenges faced by recent GLP-1 inhibitors and proposes a groundbreaking antibody-based approach to minimize side effects. Dhillon emphasizes the importance of combining effective treatments with lifestyle changes to tackle obesity's complex nature. With a commitment to rigorous clinical trials and a focus on metabolic health, he highlights Skye's potential to disrupt the weight-loss therapeutic market significantly.

Punit Dhillon, the Chairman and CEO of Skye Bioscience Inc., shares his remarkable journey from surviving a near-drowning at age nine to becoming a biotech powerhouse. He reveals the strategic insights that helped him raise over $500 million, including overcoming rejection and perfecting investor pitches. Dhillon emphasizes resilience as a crucial trait for success and draws parallels between athletic discipline and entrepreneurship. His tips for aspiring fundraisers highlight the importance of networking and preparation for effective capital raising.